Explore the words cloud of the Trials@Home project. It provides you a very rough idea of what is the project "Trials@Home" about.
The following table provides information about the project.
UNIVERSITAIR MEDISCH CENTRUM UTRECHT
|Coordinator Country||Netherlands [NL]|
|Total cost||38˙331˙269 €|
|EC max contribution||19˙036˙997 € (50%)|
1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
|Duration (year-month-day)||from 2019-09-01 to 2024-08-31|
Take a look of project's partnership.
|1||UNIVERSITAIR MEDISCH CENTRUM UTRECHT||NL (UTRECHT)||coordinator||9˙023˙087.00|
|2||JULIUS CLINICAL RESEARCH BV||NL (ZEIST)||participant||2˙788˙815.00|
|3||UNIVERSITY OF DUNDEE||UK (DUNDEE)||participant||1˙313˙842.00|
|4||FH JOANNEUM GESELLSCHAFT MBH||AT (GRAZ)||participant||879˙625.00|
|5||UNIVERSITEIT UTRECHT||NL (UTRECHT)||participant||784˙505.00|
|6||MEDICAL RESEARCH NETWORK LIMITED||UK (MILTON KEYNES)||participant||709˙802.00|
|7||STICHTING UNITED PARENT PROJECTS MUSCULAR DYSTROPHY||NL (VEENENDAAL)||participant||594˙275.00|
|8||VITAL TRANSFORMATION||BE (WEZEMBEEK OPPEM)||participant||568˙755.00|
|9||ECLINICALHEALTH LTD||UK (STIRLING)||participant||513˙750.00|
|10||ETHNIKO KENTRO EREVNAS KAI TECHNOLOGIKIS ANAPTYXIS||EL (THERMI THESSALONIKI)||participant||403˙750.00|
|11||FUNDACION PARA EL FOMENTO DE LA INVESTIGACION SANITARIA Y BIOMEDICA DE LA COMUNITAT VALENCIANA||ES (VALENCIA)||participant||400˙675.00|
|13||THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD||UK (OXFORD)||participant||250˙888.00|
|14||STICHTING MLC FOUNDATION||NL (DEN HAAG)||participant||198˙750.00|
|15||STICHTING LYGATURE||NL (UTRECHT)||participant||181˙227.00|
|16||SYDDANSK UNIVERSITET||DK (ODENSE M)||participant||110˙312.00|
|17||FEDERATION INTERNATIONALE DU DIABETE REGION EUROPE AISBL||BE (BRUXELLES)||participant||54˙937.00|
|18||ALLERGAN LIMITED||UK (MARLOW)||participant||0.00|
|19||ASTRAZENECA AB||SE (SODERTAELJE)||participant||0.00|
|20||BAYER AKTIENGESELLSCHAFT||DE (Leverkusen)||participant||0.00|
|21||BOEHRINGER INGELHEIM INTERNATIONALGMBH||DE (INGELHEIM)||participant||0.00|
|22||COVANCE CLINICAL AND PERIAPPROVAL SERVICES||BE (WOLUWE-SAINT-LAMBERT)||participant||0.00|
|23||IQVIA RDS FRANCE||FR (SAINT-OUEN)||participant||0.00|
|24||JANSSEN PHARMACEUTICA NV||BE (BEERSE)||participant||0.00|
|25||MEDTRONIC INTERNATIONAL TRADING SARL||CH (TOLOCHENAZ)||participant||0.00|
|26||NOVARTIS PHARMA AG||CH (BASEL)||participant||0.00|
|27||PFIZER LIMITED||UK (SANDWICH)||participant||0.00|
|28||SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT||FR (Chilly Mazarin)||participant||0.00|
|29||TAKEDA DEVELOPMENT CENTRE EUROPE LTD||UK (LONDON)||participant||0.00|
|30||TEVA PHARMACEUTICAL INDUSTRIES LIMITED||IL (PETACH TIVKA)||participant||0.00|
|31||UCB BIOPHARMA SRL||BE (BRUXELLES)||participant||0.00|
Clinical trials increase in size, complexity and costs. This is fuelled with the need to demonstrate effects in more complex therapeutic areas, and to detect subgroups with different benefit and safety responses. Complexities, rigid clinical control, physical distance and (perceived) burden put patient engagement under pressure. (S)low recruitment and retention compromise efficiency, generalisability and validity of traditional, site-centred trials. Remote Decentralized Clinical Trials (RDCTs) and hybrid approaches address these challenges. RDCTs are an operational strategy for technology-enhanced clinical trials, which enable (semi-)continuous data collection and real-world evidence generation, increase patient recruitment and retention and decrease patient and investigator burden and costs. Trials brought to the home of patients. Paradigmatic changes in EU clinical trial design are required to fully benefit from the digital era. Yet, the feasibility of running RDCTs needs to be rigorously demonstrated together with guidance and support measures for their execution. Trials@Home brings together a very strong consortium and will reshape clinical trial design, conduct and operations, by analysing, developing and piloting standards, recommendations and tools to define and operationalize RDCTs. Trials@Home will design and run a pan-European RDCT pilot based on: a. best practices of trials with RDCT elements, b. assessment of latest technological tools, c. the regulatory and ethical framework and potential changes required to facilitate RDCTs and d. stakeholder perspectives on the change from classical RCTs to RDCTs with strong patient involvement. The results of these assessments and the pilot will drive the formulation and dissemination of recommendations and tools for the implementation of RDCTs in Europe with the ultimate goal to improve the speed, quality and efficiency of clinical trials, and improving patients’ access to innovative treatment strategies.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TRIALS@HOME" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "TRIALS@HOME" are provided by the European Opendata Portal: CORDIS opendata.
Antibiotic Distribution and Recovery in TissueRead More
Bringing a prophylactic Ebola vaccine to licensureRead More
Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitorsRead More